Ontology highlight
ABSTRACT:
SUBMITTER: Rotundo MS
PROVIDER: S-EPMC5053632 | biostudies-other | 2016 May
REPOSITORIES: biostudies-other
Rotundo Maria Saveria MS Galeano Teresa T Tassone Pierfrancesco P Tagliaferri Pierosandro P
Oncotarget 20160501 19
We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free survival (PFS)/ time to progression (TTP) was 0.62 in favor of mTOR-I+HT arm (95% confidence interval [CI] 0.55-0.70; p<0.0001). There was significant heterogeneity for PFS/TTP (Cochran's Q 32, p<0.0001, I2 ...[more]